KR20130052740A - ｃ－Ｍｅｔ 억제제로서 ６－（１－메틸－１Ｈ－피라졸－４－일）－３－（２－메틸－２Ｈ－인다졸－５－일티오）－［１,２,４］트리아졸로［４,３－Ｂ］피리다진 - Google Patents
ｃ－Ｍｅｔ 억제제로서 ６－（１－메틸－１Ｈ－피라졸－４－일）－３－（２－메틸－２Ｈ－인다졸－５－일티오）－［１,２,４］트리아졸로［４,３－Ｂ］피리다진 Download PDFInfo
- Publication number
- KR20130052740A KR20130052740A KR1020137002382A KR20137002382A KR20130052740A KR 20130052740 A KR20130052740 A KR 20130052740A KR 1020137002382 A KR1020137002382 A KR 1020137002382A KR 20137002382 A KR20137002382 A KR 20137002382A KR 20130052740 A KR20130052740 A KR 20130052740A
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- cancer
- methyl
- compounds
- met
- Prior art date
Links
- 0 C[n]1ncc(-c(cc2)n[n]3c2nnc3*)c1 Chemical compound C[n]1ncc(-c(cc2)n[n]3c2nnc3*)c1 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36933510P | 2010-07-30 | 2010-07-30 | |
| US61/369,335 | 2010-07-30 | ||
| PCT/US2011/044926 WO2012015677A1 (en) | 2010-07-30 | 2011-07-22 | 6- (1-methyl-1h-pyrazol-4-yl)-3-(2-methyl-2h-indazol-5- |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20130052740A true KR20130052740A (ko) | 2013-05-23 |
Family
ID=44513148
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020137002382A KR20130052740A (ko) | 2010-07-30 | 2011-07-22 | ｃ－Ｍｅｔ 억제제로서 ６－（１－메틸－１Ｈ－피라졸－４－일）－３－（２－메틸－２Ｈ－인다졸－５－일티오）－［１,２,４］트리아졸로［４,３－Ｂ］피리다진 |
Country Status (15)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2870178B1 (en) * | 2012-05-09 | 2017-07-12 | Eli Lilly and Company | Anti-c-met antibodies |
| CN103122000B (zh) | 2012-09-03 | 2013-12-25 | 中美冠科生物技术（太仓）有限公司 | 用作抗肿瘤药物的高选择性的c-Met激酶抑制剂 |
| TWI667233B (zh) | 2013-12-19 | 2019-08-01 | 德商拜耳製藥公司 | 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途 |
| US10386376B2 (en) | 2015-11-09 | 2019-08-20 | Jeimei, Llc | Sample container with integrated test strip |
| CN106924260B (zh) * | 2015-12-31 | 2018-05-25 | 北京浦润奥生物科技有限责任公司 | 化合物在制备用于治疗脑胶质瘤的药物中的用途 |
| EA202192575A1 (ru) | 2019-03-21 | 2022-01-14 | Онксео | Соединения dbait в сочетании с ингибиторами киназ для лечения рака |
| US20220401436A1 (en) | 2019-11-08 | 2022-12-22 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007064797A2 (en) * | 2005-11-30 | 2007-06-07 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-met and uses thereof |
| US8217177B2 (en) | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| PE20080403A1 (es) * | 2006-07-14 | 2008-04-25 | Amgen Inc | Derivados heterociclicos fusionados y metodos de uso |
| CN101553490A (zh) * | 2006-10-23 | 2009-10-07 | Sgx药品公司 | 用作蛋白激酶调节剂的二环三唑类化合物 |
| KR101083177B1 (ko) | 2006-10-23 | 2011-11-11 | 에스지엑스 파마슈티컬스, 인코포레이티드 | 트리아졸로-피리다진 단백질 키나제 조정제 |
| DK2084162T3 (da) * | 2006-10-23 | 2012-10-01 | Sgx Pharmaceuticals Inc | Bicykliske triazoler som proteinkinasemodulatorer |
| PA8792501A1 (es) * | 2007-08-09 | 2009-04-23 | Sanofi Aventis | Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met. |
| PE20091468A1 (es) | 2008-02-28 | 2009-10-22 | Novartis Ag | DERIVADOS DE 3-METIL-IMIDAZO-[1,2-b]-PIRIDAZINA |
-
2011
- 2011-07-20 AR ARP110102632A patent/AR085183A1/es unknown
- 2011-07-22 WO PCT/US2011/044926 patent/WO2012015677A1/en active Application Filing
- 2011-07-22 EA EA201270818A patent/EA201270818A1/ru unknown
- 2011-07-22 MX MX2013001247A patent/MX2013001247A/es not_active Application Discontinuation
- 2011-07-22 BR BR112013002211A patent/BR112013002211A2/pt not_active IP Right Cessation
- 2011-07-22 US US13/188,496 patent/US8268836B2/en not_active Expired - Fee Related
- 2011-07-22 KR KR1020137002382A patent/KR20130052740A/ko not_active Application Discontinuation
- 2011-07-22 TW TW100126076A patent/TWI431008B/zh not_active IP Right Cessation
- 2011-07-22 JP JP2013521838A patent/JP5738412B2/ja not_active Expired - Fee Related
- 2011-07-22 AU AU2011282973A patent/AU2011282973B2/en not_active Expired - Fee Related
- 2011-07-22 EP EP11741372.4A patent/EP2598144B1/en not_active Not-in-force
- 2011-07-22 CN CN2011800371928A patent/CN103002898A/zh active Pending
- 2011-07-22 CA CA2805494A patent/CA2805494A1/en not_active Abandoned
- 2011-07-22 ES ES11741372.4T patent/ES2516940T3/es active Active
-
2012
- 2012-12-31 IN IN2924MUN2012 patent/IN2012MN02924A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2598144A1 (en) | 2013-06-05 |
| JP2013532687A (ja) | 2013-08-19 |
| TW201219393A (en) | 2012-05-16 |
| ES2516940T3 (es) | 2014-10-31 |
| CA2805494A1 (en) | 2012-02-02 |
| US20120028984A1 (en) | 2012-02-02 |
| MX2013001247A (es) | 2013-03-18 |
| WO2012015677A9 (en) | 2012-12-13 |
| AR085183A1 (es) | 2013-09-18 |
| US8268836B2 (en) | 2012-09-18 |
| AU2011282973A1 (en) | 2013-01-10 |
| BR112013002211A2 (pt) | 2016-05-24 |
| EP2598144B1 (en) | 2014-08-13 |
| AU2011282973B2 (en) | 2014-03-20 |
| JP5738412B2 (ja) | 2015-06-24 |
| TWI431008B (zh) | 2014-03-21 |
| EA201270818A1 (ru) | 2013-05-30 |
| IN2012MN02924A (US20070167479A1-20070719-C00034.png) | 2015-06-12 |
| WO2012015677A1 (en) | 2012-02-02 |
| CN103002898A (zh) | 2013-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10227329B2 (en) | Compounds useful for treating disorders related to RET | |
| KR20130052740A (ko) | ｃ－Ｍｅｔ 억제제로서 ６－（１－메틸－１Ｈ－피라졸－４－일）－３－（２－메틸－２Ｈ－인다졸－５－일티오）－［１,２,４］트리아졸로［４,３－Ｂ］피리다진 | |
| EP2850082B1 (en) | 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido(2,3-d)pyrimidin-6-yl)phenyl)urea as Raf kinase inhibitor for the treatment of cancer | |
| JP7240784B2 (ja) | ８，９－ジヒドロイミダゾール［１，２－ａ］ピリミド［５，４－ｅ］ピリミジン－５（６Ｈ）－ケトン類化合物 | |
| EP2931722B1 (en) | Substituted 1h-pyrrolo [2,3-b]pyridine and 1h-pyrazolo [3, 4-b]pyridine derivatives as salt inducible kinase 2 (sik2) inhibitors | |
| RU2326882C2 (ru) | Пиримидиновые соединения, обладающие антипролиферативной активностью (ii) | |
| EP3546460B1 (en) | Pyrimido[5,4-b]indolizine or pyrimido[5,4-b]pyrrolizine compound, preparation method and use thereof | |
| CN109689641B (zh) | 一种取代的2-氢-吡唑衍生物的晶型、盐型及其制备方法 | |
| WO2014135028A1 (zh) | 吡啶并嘧啶或嘧啶并嘧啶类化合物、其制备方法、药物组合物及其用途 | |
| WO2012138809A1 (en) | Heterocyclic compounds as kinase inhibitors | |
| EP3661935A1 (en) | Substituted pyrazolopyrimidines useful as kinases inhibitors | |
| CN110036012A (zh) | 吡啶并[3,4-d]嘧啶衍生物及其药学上可接受的盐 | |
| CN109641902B (zh) | 可用作人pde1抑制剂的三唑并吡嗪酮衍生物 | |
| Liang et al. | Discovery of Pyrrolo [2, 3-d] pyrimidine derivatives as potent and selective colony stimulating factor 1 receptor kinase inhibitors | |
| CN113717245A (zh) | 含有2,8,9-三取代-9h-嘌呤结构片段的egfr降解剂及其盐和应用 | |
| CN108329321A (zh) | 一种新颖的吡唑并［3，4－d］嘧啶类JAK激酶抑制剂的制备与应用 | |
| Carrasco et al. | Discovery of novel 2, 3, 5-trisubstituted pyridine analogs as potent inhibitors of IL-1β via modulation of the p38 MAPK signaling pathway | |
| WO2023024545A1 (zh) | Fgfr4抑制剂、组合物及其在药物制备中的用途 | |
| EP3661936B1 (en) | [1,2,4]triazolo[4,3-a]pyrazin-6(5h)-one derivatives | |
| JP7053654B2 (ja) | ＰＩ３Ｋβ阻害剤としてのキノキサリン及びピリドピラジン誘導体 | |
| KR100714370B1 (ko) | 항종양 활성을 갖는〔1,2,4〕―트리아졸로〔4,3―ｃ〕퀴나졸린 유도체 | |
| CN116425745A (zh) | 一种rock抑制剂的盐及盐的晶型、组合物和药物用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E601 | Decision to refuse application |